Burcon NutraScience Competitors

Burcon NutraScience (TSE:BU) and Trillium Therapeutics (TSE:TRIL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, dividends and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Burcon NutraScience and Trillium Therapeutics, as provided by MarketBeat.com.

Burcon NutraScience currently has a consensus target price of C$5.00, indicating a potential downside of 7.75%. Trillium Therapeutics has a consensus target price of C$25.00, indicating a potential upside of 91.42%. Given Trillium Therapeutics' higher possible upside, analysts clearly believe Trillium Therapeutics is more favorable than Burcon NutraScience.

Profitability

This table compares Burcon NutraScience and Trillium Therapeutics' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Burcon NutraScience and Trillium Therapeutics' revenue, earnings per share and valuation.

Burcon NutraScience has higher earnings, but lower revenue than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Summary

Burcon NutraScience beats Trillium Therapeutics on 5 of the 7 factors compared between the two stocks.

Concordia International (TSE:CXR) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.

Profitability

This table compares Concordia International and Burcon NutraScience's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Concordia International and Burcon NutraScience's revenue, earnings per share and valuation.

Concordia International has higher revenue and earnings than Burcon NutraScience. Concordia International is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Concordia International and Burcon NutraScience, as provided by MarketBeat.

Burcon NutraScience has a consensus price target of C$5.00, indicating a potential downside of 7.75%.

Summary

Concordia International beats Burcon NutraScience on 3 of the 5 factors compared between the two stocks.

Burcon NutraScience (TSE:BU) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.

Profitability

This table compares Burcon NutraScience and Aptose Biosciences' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Burcon NutraScience and Aptose Biosciences' gross revenue, earnings per share (EPS) and valuation.

Burcon NutraScience has higher revenue and earnings than Aptose Biosciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Burcon NutraScience and Aptose Biosciences, as provided by MarketBeat.com.

Burcon NutraScience presently has a consensus price target of C$5.00, suggesting a potential downside of 7.75%. Aptose Biosciences has a consensus price target of C$12.00, suggesting a potential upside of 81.54%. Given Aptose Biosciences' higher probable upside, analysts clearly believe Aptose Biosciences is more favorable than Burcon NutraScience.

Summary

Burcon NutraScience beats Aptose Biosciences on 3 of the 5 factors compared between the two stocks.

Burcon NutraScience (TSE:BU) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Burcon NutraScience and Theratechnologies, as provided by MarketBeat.com.

Burcon NutraScience presently has a consensus price target of C$5.00, suggesting a potential downside of 7.75%. Theratechnologies has a consensus price target of C$3.75, suggesting a potential downside of 21.38%. Given Burcon NutraScience's stronger consensus rating and higher probable upside, equities analysts clearly believe Burcon NutraScience is more favorable than Theratechnologies.

Valuation & Earnings

This table compares Burcon NutraScience and Theratechnologies' gross revenue, earnings per share (EPS) and valuation.

Burcon NutraScience has higher earnings, but lower revenue than Theratechnologies. Theratechnologies is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Burcon NutraScience and Theratechnologies' net margins, return on equity and return on assets.

Summary

Burcon NutraScience beats Theratechnologies on 7 of the 8 factors compared between the two stocks.

BELLUS Health (TSE:BLU) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for BELLUS Health and Burcon NutraScience, as provided by MarketBeat.

Burcon NutraScience has a consensus price target of C$5.00, suggesting a potential downside of 7.75%. Given Burcon NutraScience's stronger consensus rating and higher probable upside, analysts plainly believe Burcon NutraScience is more favorable than BELLUS Health.

Earnings and Valuation

This table compares BELLUS Health and Burcon NutraScience's gross revenue, earnings per share (EPS) and valuation.

Burcon NutraScience has lower revenue, but higher earnings than BELLUS Health. BELLUS Health is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BELLUS Health and Burcon NutraScience's net margins, return on equity and return on assets.

Summary

Burcon NutraScience beats BELLUS Health on 6 of the 8 factors compared between the two stocks.

Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Earnings & Valuation

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and Burcon NutraScience's revenue, earnings per share (EPS) and valuation.

Burcon NutraScience has lower revenue, but higher earnings than Nuvo Pharmaceuticals Inc. (NRI.TO). Nuvo Pharmaceuticals Inc. (NRI.TO) is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Nuvo Pharmaceuticals Inc. (NRI.TO) and Burcon NutraScience, as reported by MarketBeat.

Burcon NutraScience has a consensus target price of C$5.00, indicating a potential downside of 7.75%. Given Burcon NutraScience's higher possible upside, analysts clearly believe Burcon NutraScience is more favorable than Nuvo Pharmaceuticals Inc. (NRI.TO).

Profitability

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and Burcon NutraScience's net margins, return on equity and return on assets.

Summary

Burcon NutraScience beats Nuvo Pharmaceuticals Inc. (NRI.TO) on 5 of the 6 factors compared between the two stocks.